Discovery may hike stem cell transplants.

Abstract:

:Researchers identified a small molecule that stimulates the production of stem cells in umbilical cord blood, potentially expanding treatment options for adults with hematologic cancers.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2014-153

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

1361

issue

12

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2014-153

journal_volume

4

pub_type

新闻
  • Antiangiogenic drugs increase xenograft aggressiveness.

    abstract::Treating human breast cancer xenografts in mice with bevacizumab or sunitinib has increased the population of cancer stem cells found in the tumors. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2012-013

    authors:

    更新日期:2012-03-01 00:00:00

  • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

    abstract::CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples. We conducted paired baseline and end-of-treatment circulating tumor DNA seq...

    journal_title:Cancer discovery

    pub_type: 杂志文章,随机对照试验

    doi:10.1158/2159-8290.CD-18-0264

    authors: O'Leary B,Cutts RJ,Liu Y,Hrebien S,Huang X,Fenwick K,André F,Loibl S,Loi S,Garcia-Murillas I,Cristofanilli M,Huang Bartlett C,Turner NC

    更新日期:2018-11-01 00:00:00

  • Cancer "Clock" Opens New Therapeutic Avenues.

    abstract::Long ignored, the importance of circadian rhythms-the focus of this year's Nobel Prize in Physiology or Medicine-is beginning to gain attention from researchers interested in cancer prevention, drug discovery, and therapeutic optimization. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-149

    authors:

    更新日期:2017-12-01 00:00:00

  • Stabilization of a closed kinase conformation induces RAF dimerization.

    abstract::BRAF inhibitors stabilize a closed, rigid RAF kinase conformation that facilitates dimerization. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2013-114

    authors:

    更新日期:2013-07-01 00:00:00

  • LXR Agonism Depletes MDSCs to Promote Antitumor Immunity.

    abstract::LXR activation reduces immunosuppressive MDSCs to activate antitumor cytotoxic T cells. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2018-010

    authors:

    更新日期:2018-03-01 00:00:00

  • Mutations in ERBB3 drive tumorigenesis.

    abstract::Somatic ERBB3 hot-spot mutations promote oncogenic signaling in a subset of human tumors. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2013-107

    authors:

    更新日期:2013-07-01 00:00:00

  • Molecular dissection of microsatellite instable colorectal cancer.

    abstract:UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-12-0471

    authors: Vilar E,Tabernero J

    更新日期:2013-05-01 00:00:00

  • CD10+GPR77+ Cancer-Associated Fibroblasts Promote Chemoresistance.

    abstract::CD10 and GPR77 define a cancer-associated fibroblast (CAF) subset that sustains cancer stemness. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2018-019

    authors:

    更新日期:2018-03-01 00:00:00

  • AMG 510 First to Inhibit "Undruggable" KRAS.

    abstract::Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG1...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-073

    authors:

    更新日期:2019-08-01 00:00:00

  • EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

    abstract:UNLABELLED:Glioblastomas (GBM) with EGFR amplification represent approximately 50% of newly diagnosed cases, and recent studies have revealed frequent coexistence of multiple EGFR aberrations within the same tumor, which has implications for mutation cooperation and treatment resistance. However, bulk tumor sequencing ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-13-0879

    authors: Francis JM,Zhang CZ,Maire CL,Jung J,Manzo VE,Adalsteinsson VA,Homer H,Haidar S,Blumenstiel B,Pedamallu CS,Ligon AH,Love JC,Meyerson M,Ligon KL

    更新日期:2014-08-01 00:00:00

  • Brain May Prime Metastatic Cell Growth.

    abstract::Metastasizing tumor cells lose expression of the tumor suppressor PTEN at a much higher rate when they enter the brain compared to other organs, suggesting that the brain's unique microenvironment may prime metastatic cells for aggressive growth, a recent study reports. The findings may have implications for developin...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-163

    authors:

    更新日期:2016-01-01 00:00:00

  • Enzalutamide Bests Older NSAAs in mHSPC.

    abstract::According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-066

    authors:

    更新日期:2019-08-01 00:00:00

  • Cancer Care Goes Virtual in Response to COVID-19.

    abstract::Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-027

    authors:

    更新日期:2020-06-01 00:00:00

  • Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

    abstract:UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0124

    authors: Tanaka K,Babic I,Nathanson D,Akhavan D,Guo D,Gini B,Dang J,Zhu S,Yang H,De Jesus J,Amzajerdi AN,Zhang Y,Dibble CC,Dan H,Rinkenbaugh A,Yong WH,Vinters HV,Gera JF,Cavenee WK,Cloughesy TF,Manning BD,Baldwin AS,Mi

    更新日期:2011-11-01 00:00:00

  • Pembrolizumab Approved for Hodgkin Lymphoma.

    abstract::The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers-and for children. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-044

    authors:

    更新日期:2017-05-01 00:00:00

  • Pazopanib outscores sunitinib on tolerability.

    abstract::In a phase III trial for patients with metastatic renal cell carcinoma, pazopanib and sunitinib offered comparable progression-free survival, but pazopanib scored higher on quality-of-life indices. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2013-131

    authors:

    更新日期:2014-01-01 00:00:00

  • HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.

    abstract::Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-11-0261

    authors: Ciardiello F,Normanno N

    更新日期:2011-11-01 00:00:00

  • Durable Responses with Brentuximab Vedotin in cHL.

    abstract::According to survival results from a phase II trial of brentuximab vedotin, 34 patients with relapsed or refractory classic Hodgkin lymphoma had a complete response with this CD30-targeting antibody-drug conjugate; 13 remain in remission 5 years later. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-100

    authors:

    更新日期:2016-09-01 00:00:00

  • Improved survival ends nivolumab trial early.

    abstract::A phase III trial testing nivolumab to treat advanced melanoma was stopped early due to improved overall survival compared with standard chemotherapy. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-NB2014-104

    authors:

    更新日期:2014-09-01 00:00:00

  • First CDK 4/6 Inhibitor Heads to Market.

    abstract::The FDA granted accelerated approval to palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women who have not yet received endocrine-based therapy. Palbociclib is the first cell cycle-targeting CDK 4/6 inhibitor to reach the market. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-028

    authors:

    更新日期:2015-04-01 00:00:00

  • Resistance emerges to second-generation antiandrogens in prostate cancer.

    abstract::The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-13-0405

    authors: Nelson WG,Yegnasubramanian S

    更新日期:2013-09-01 00:00:00

  • Relapse-Driving AML Cells Exhibit Pyrimidine-Synthesis Dependency.

    abstract::Residual acute myeloid leukemia (AML) cells required bone marrow stromal cell-derived aspartate. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-118

    authors:

    更新日期:2020-10-01 00:00:00

  • Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.

    abstract::Agonistic antibodies targeting CD137 have been clinically unsuccessful due to systemic toxicity. Because conferring tumor selectivity through tumor-associated antigen limits its clinical use to cancers that highly express such antigens, we exploited extracellular adenosine triphosphate (exATP), which is a hallmark of ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0328

    authors: Kamata-Sakurai M,Narita Y,Hori Y,Nemoto T,Uchikawa R,Honda M,Hironiwa N,Taniguchi K,Shida-Kawazoe M,Metsugi S,Miyazaki T,Wada NA,Ohte Y,Shimizu S,Mikami H,Tachibana T,Ono N,Adachi K,Sakiyama T,Matsushita T,Kadono

    更新日期:2020-08-25 00:00:00

  • Genomic Screens Identify Genes That Regulate MHC-I Expression in DLBCL.

    abstract::MHC-I and MHC-II regulators in lymphomas, some of which had subtype or tumor specificity, were identified. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-178

    authors:

    更新日期:2020-12-11 00:00:00

  • New FDA Center May Speed Approval Process.

    abstract::The FDA's new Oncology Center of Excellence is aimed at consolidating the approval processes for new cancer drugs, biologics, and devices. Richard Pazdur, MD, current director of the agency's Office of Hematology and Oncology Products within the Center for Drug Evaluation and Research will serve as the new center's ac...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-092

    authors:

    更新日期:2016-09-01 00:00:00

  • LKB1 Inactivation Promotes ROS-Induced Plasticity in NSCLC.

    abstract::LKB1 inactivation generates a redox imbalance that promotes ADC-to-SCC transdifferentiation in NSCLC. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2015-089

    authors:

    更新日期:2015-07-01 00:00:00

  • Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

    abstract::Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-16-1056

    authors: Snyder A,Wolchok JD

    更新日期:2016-11-01 00:00:00

  • By the Numbers: New Biologic License Application Filings and Drug Approvals, 2007-2016.

    abstract::The FDA approved 22 novel drugs in 2016, down from 45 in 2015. Four of the new therapies are for cancer treatment, and two are for cancer diagnosis. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-003

    authors:

    更新日期:2017-02-01 00:00:00

  • Nanostars amplify ability to image cancer.

    abstract::A new nanoparticle design may make cancer detection possible without the use of molecular markers of tumor cells. The star-shaped probe detected five different cancers in mouse models, according to a new study. By using nanostars to boost surface-enhanced resonance Raman scattering signals, the technique highlighted t...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-022

    authors:

    更新日期:2015-04-01 00:00:00

  • Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.

    abstract::HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

    journal_title:Cancer discovery

    pub_type: 评论,信件

    doi:10.1158/2159-8290.CD-RW2016-052

    authors:

    更新日期:2016-05-01 00:00:00